Hepatic and Renal Deterioration

Pharmacists emphasised the clinical value of identifying hepatic and renal risk earlier in the treatment course so that monitoring can be tailored accordingly. The ML-CDSS predicts a patient's risk of hepatic and renal deterioration using blood chemistry data collected at chemotherapy cycles three and four. Behavioural factors such as diet and physical activity, as well as comorbidities, can influence hepatic and renal function but are not captured by the ML-CDSS's blood chemistry-only inputs.